Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China

NCT06155084 is registered in ClinicalTrials.gov with Hinova Pharmaceuticals Inc. as lead sponsor.

NCT NCT06155084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06155084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China
Lead sponsor
Hinova Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 26, 2023
Completion date
September 30, 2026
Enrollment
84 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer